Form 4: Medifast VP Finance & CAO Reports Stock Transactions

Jonathan Barrett MacKenzie, Medifast's VP of Finance & CAO, reported the acquisition of restricted stock units and the disposition of shares for tax obligations.

Summary

• Jonathan Barrett MacKenzie, VP, Finance & CAO of Medifast, Inc. (MED), reported several transactions involving the company's common stock.
• On March 25, 2026, MacKenzie acquired 10,830 restricted stock units (RSUs) at a price of $0, granted under the 2012 Share Incentive Plan.
• These RSUs will vest in three equal annual installments, commencing on the first anniversary of the grant date.
• MacKenzie also disposed of shares to cover withholding taxes associated with the vesting of previous restricted stock unit grants.
• Dispositions included 198 shares at $9.62 on March 13, 2026, 70 shares at $10.05 on March 17, 2026, and 862 shares at $9.59 on March 25, 2026.
• Following these transactions, MacKenzie's direct beneficial ownership of common stock increased from 10,008 shares to 20,838 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine executive compensation event, slightly positive as it aligns management incentives with long-term shareholder value through restricted stock unit grants.

Positives

• The grant of 10,830 restricted stock units aligns the executive's long-term interests with those of shareholders, incentivizing performance and retention.
• The acquisition of RSUs at a $0 price indicates a compensation component designed to reward future performance and commitment to the company.

Negatives

• The disposition of shares to cover withholding taxes is a standard procedure upon RSU vesting and does not reflect a negative outlook on the company.

Future Outlook

The acquired restricted stock units are scheduled to vest in three equal annual installments, beginning on the first anniversary of the grant date, indicating a multi-year incentive structure for the executive.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units and subsequent tax-related dispositions are common practices in executive compensation across various industries, aiming to align executive incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a component of executive compensation is a widely adopted practice, comparable to compensation structures seen in companies like Herbalife Nutrition Ltd. (HLF) or WW International, Inc. (WW), which also utilize equity-based incentives to retain and motivate key personnel.
• The disposition of shares to cover tax obligations upon RSU vesting is a standard and expected event, consistent with practices observed across publicly traded companies globally when equity awards vest.

Stakeholder Impact

• Shareholders: The RSU grant aligns the interests of a key executive with long-term shareholder value, potentially fostering sustained performance.
• Employees: This reflects a standard executive compensation practice, which can influence overall compensation philosophy within the company.

Next Steps

• The restricted stock units granted on March 25, 2026, will begin to vest in three equal annual installments starting on the first anniversary of the grant date.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically an RSU grant and tax-related share dispositions. Such transactions are standard and do not typically indicate a change in the company's fundamental outlook or warrant a shift in investment recommendation based solely on this filing. Investors should continue to monitor broader company performance and market conditions.

Keywords

Medifast, MED, Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Executive Compensation, Stock Ownership, Jonathan Barrett MacKenzie